Mobile

Phase 3 study to evaluate safety and effectiveness of oral Apremilast (CC-10004) in patients with Psoriatic Arthritis who have not been previously treated with disease-modifiying antirheumatic drugs

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-020324-22

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of the study is to evaluate the clinical efficacy of 2 doses of apremilast (20 mg or 30 mg orally BID) compared with placebo, on the signs and symptoms of psoriatic arthritis (PsA) after 16 weeks' administration

Critère d'inclusion

  • Psoriatic arthritis, an inflammatory arthritis that occurs in 6 to 39% of patients with psoriasis

Liens